Embryonic stem cells lacking the epigenetic regulator Cfp1 are hypersensitive to DNA-damaging agents and exhibit decreased Ape1/Ref-1 protein expression and endonuclease activity

DNA Repair

Volumn 8, Issue 12, 2009, Pages 1411-1423

  Tate, Courtney M ^a   Fishel, Melissa L ^a   Holleran, Julianne L ^b   Egorin, Merrill J ^b   Skalnik, David G ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Ape1 Ref 1; Cfp1; Chromatin; DNA damaging agents; Epigenetic regulation

Indexed keywords

CISPLATIN; COBALT 60; COMPLEMENTARY DNA; CXXC FINGER PROTEIN 1; CYTOSINE; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; ENDONUCLEASE; ETOPOSIDE; GENOMIC DNA; HISTONE H2AX; HYDROGEN PEROXIDE; MESYLIC ACID METHYL ESTER; METHOTREXATE; PACLITAXEL; REDOX EFFECTOR FACTOR 1; RIBONUCLEASE A; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CHROMATIN STRUCTURE; CONTROLLED STUDY; DNA BINDING; DNA DAMAGE; DNA REPAIR; EMBRYO; EMBRYONIC STEM CELL; ENZYME ACTIVITY; ENZYME ASSAY; EPIGENETICS; EXCISION REPAIR; GENOTOXICITY; IONIZING RADIATION; METHYLATION; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ANIMALS; CELL LINE; CISPLATIN; DEOXYRIBONUCLEASE I; DNA DAMAGE; DNA METHYLATION; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; EMBRYONIC STEM CELLS; MICE; PROTEIN BINDING; TRANS-ACTIVATORS;

MAMMALIA; MURINAE;

EID: 70450221503     PISSN: 15687864     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dnarep.2009.09.011     Document Type: Article

References (98)

1. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 21 (2002) 5400-5413
2. Jones P.A., and Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Genet. 3 (2002) 415-428
3. Baylin S.B., and Herman J.G. DNA hypermethylation in tumorigenesis. Trends Genet. 16 (2000) 168-173
4. Gaudet F., Hodgson J.G., Eden A., Jackson-Grusby L., Dausman J., Gray J.W., Leonhardt H., and Jaenisch R. Induction of tumors in mice by genomic hypomethylation. Science 300 (2003) 489-492
5. Trinh B.N., Long T.I., Nickel A.E., Shibata D., and Laird P.W. DNA methyltransferase deficiency modifies cancer susceptibility in mice lacking DNA mismatch repair. Mol. Cell. Biol. 22 (2002) 2906-2917
6. Eden A., Gaudet F., Waghmare A., and Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300 (2003) 455
7. Litz C.E., and Etzell Aberrant J. DNA methylation of genomic regions translocated in myeloid malignancies. Leuk. Lymphoma 30 (1998) 1-9
8. Hennessy B.T., Garcia-Manero G., Kantarjian H.M., and Giles F.J. DNA methylation in haematological malignancies: the role of decitabine. Expert Opin. Investig. Drugs 12 (2003) 1985-1993
9. Lyons J., Bayar E., Fine G., McCullar M., Rolens R., Rubinfeld J., and Rosenfeld C. Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies. Curr. Opin. Investig. Drugs 4 (2003) 1442-1450
10. Wijermans P., Lubbert M., Verhoef G., Bosly A., Ravoet C., Andre M., and Ferrant A. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J. Clin. Oncol. 18 (2000) 956-962
11. Ataian Y., and Krebs J.E. Five repair pathways in one context: chromatin modification during DNA repair. Biochem. Cell. Biol. 84 (2006) 490-504
12. Christmann M., Tomici M.T., Roos W.P., and Kaina B. Mechanisms of human DNA repair: an update. Toxicology 193 (2003) 3-34
13. Coates P.J., Lorimore S.A., and Wright E.G. Cell and tissue responses to genotoxic stress. J. Pathol. 205 (2005) 221-235
14. Fleck O., and Nielsen O. DNA repair. J. Cell Sci. 117 (2004) 515-517
15. Zharkov D.O. Base excision DNA repair. Cell. Mol. Life Sci. 65 (2008) 1544-1565
16. Bapat A., Fishel M., and Kelley M.R. Going Ape as an approach to cancer therapeutics. Antioxid. Redox Signal (2008)
17. Fishel M.L., He Y., Reed A.M., Chin-Sinex H., Hutchins G.D., Mendonca M.S., and Kelley M.R. Knockdown of the DNA repair and redox signaling protein Ape1/Ref-1 blocks ovarian cancer cell and tumor growth. DNA Repair 7 (2008) 177-186
18. Fishel M.L., He Y., Smith M.L., and Kelley M.R. Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide. Clin. Cancer Res. 13 (2007) 260-267
19. Fishel M.L., and Kelley M.R. The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target. Mol. Aspects Med. 28 (2007) 375-395
20. Jiang Y., Guo C., Vasko M.R., and Kelley M.R. Implications of apurinic/apyrimidinic endonuclease in reactive oxygen signaling response after cisplatin treatment of dorsal root ganglion neurons. Cancer Res. 68 (2008) 6425-6434
21. Madhusudan S., Smart F., Shrimpton P., Parsons J.L., Gardiner L., Houlbrook S., Talbot D.C., Hammonds T., Freemont P.A., Sternberg M.J., Dianov G.L., and Hickson I.D. Isolation of a small molecule inhibitor of DNA base excision repair. Nucleic Acids Res. 33 (2005) 4711-4724
22. Ono Y., Furuta T., Ohmoto T., Akiyama K., and Seki S. Stable expression in rat glioma cells of sense and antisense nucleic acids to a human multifunctional DNA repair enzyme, APEX nuclease. Mutat. Res. 315 (1994) 55-63
23. Walker L.J., Craig R.B., Harris A.L., and Hickson I.D. A role for the human DNA repair enzyme HAP1 in protection against DNA damaging agents and hypoxic stress. Nucleic Acids Res. 22 (1994) 4884-4889
24. Orphanides G., and Reinberg D. RNA polymerase II elongation through chromatin. Nature 407 (2000) 471-475
25. Thoma F. Light and dark in chromatin repair: repair of UV-induced DNA lesions by photolyase and nucleotide excision repair. EMBO J. 18 (1999) 6585-6598
26. Martin C.C., and Zhang Y. The diverse functions of histone lysine methylation. Nat. Rev. Mol. Cell. Biol. 6 (2005) 838-849
27. Peterson C.L., and Laniel M.-A. Histones and histone modifications. Curr. Biol. 14 (2004) R546-R551
28. Roth S.Y., Denu J.M., and Allis C.D. Histone acetyltransferases. Annu. Rev. Biochem. 70 (2001) 81-120
29. Shilatifard A. Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression. Annu. Rev. Biochem. 75 (2006) 243-369
30. Singal R., and Ginder G.D. DNA methylation. Blood 93 (1999) 4059-4070
31. Li E., Bestor T.H., and Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 69 (1992) 915-926
32. Escargueil A.E., Soares D.G., Salvador M., Larsen A.K., and Henriques J.A.P. What histone code for DNA repair?. Mutat. Res. 658 (2008) 259-270
33. Butler J.S., Lee J.-H., and Skalnik D.G. CFP1 interacts with DNMT1 independently of association with the Setd1 histone H3K4 methyltransferase complexes. DNA Cell Biol. 27 (2008) 533-543
34. Lee J.-H., and Skalnik D.G. CpG-binding protein (CXXC finger protein 1) is a component of the mammalian Set1 histone H3-Lys4 methyltransferase complex, the analogue of the yeast Set1/COMPASS complex. J. Biol. Chem. 280 (2005) 41725-41731
35. Lee J.-H., Tate C.M., You J.Y., and Skalnik D.G. Identification and characterization of the human Set1B histone H3-Lys4 methyltransferase complex. J. Biol. Chem. 282 (2007) 13419-13428
36. Voo K.S., Carlone D.L., Jacobsen B.M., Flodin A., and Skalnik D.G. Cloning of a mammalian transcriptional activator that binds unmethylated CpG motifs and shares a CXXC domain with DNA methyltransferase, human trithorax, and methyl-CpG binding domain protein 1. Mol. Cell Biol. 20 (2000) 2108-2121
37. Lee J.-H., Voo K.S., and Skalnik D.G. Identification and characterization of the DNA binding domain of CpG-binding protein. J. Biol. Chem. 276 (2001) 44669-44676
38. Carlone D.L., and Skalnik D.G. CpG binding protein is crucial for early embryonic development. Mol. Cell. Biol. 21 (2001) 7601-7606
39. Carlone D.L., Lee J.-H., Young S.R.L., Dobrota E., Butler J.S., Ruiz J., and Skalnik D.G. Reduced genomic cytosine methylation and defective cellular differentiation in embryonic stem cells lacking CpG binding protein. Mol. Cell. Biol. 25 (2005) 4881-4891
40. Fang J., Nakamura H., and Iyer A.K. Tumor-targeted induction of oxystress for cancer therapy. J. Drug Target 15 (2007) 475-486
41. Meynard D., Le Morvan V., Bonnet J., and Robert J. Functional analysis of the gene expression profiles of colorectal cancer cell lines in relation to oxaliplatin and cisplatin cytotoxicity. Oncol. Rep. 17 (2007) 1213-1221
42. Yang S., Irani K., Heffron S.E., Jurnak F., and Meyskens F.L. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor. Mol. Cancer Ther. 4 (2005) 1923-1935
43. Carlone D.S., Hart S.R.L., Ladd P.D., and Skalnik D.G. Cloning and characterization of the gene encoding the mouse homologue of CpG binding protein. Gene 295 (2002) 71-77
44. Balaghi M., and Wagner C. DNA methylation in folate deficiency: use of CpG methylase. Biochem. Biophys. Res. Commun. 193 (1993) 1184-1190
45. Fowler B.M., Giuliano A.R., Piyathilake C., Nour M., and Hatch K. Hypomethylation in cervical tissue: is there a correlation with folate status?. Cancer Epidemiol. Biomarkers Prev. 7 (1998) 901-906
46. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
47. Kreklau E.L., Limp-Foster M., Liu N., Xu Y., Kelley M.R., and Erickson L.C. A novel fluorometric oligonucleotide assay to measure O6-methylguanine DNA methyltransferase, methylpurine DNA glycosylase, 8-oxoguanine DNA glycosylase and abasic endonuclease activities: DNA repair status in human breast carcinoma cells overexpressing methylpurine DNA glycosylase. Nucleic Acids Res. 29 (2001) 2558-2566
48. Rabik C.A., Fishel M.L., Holleran J.L., Kasza K., Kelley M.R., Egorin M.J., and Dolan M.E. Enhancement of cisplatin [cis-diammine dichloroplatinum (II)] cytotoxicity by O6-benzylguanine involves endoplasmic reticulum stress. J. Pharmacol. Exp. Ther. 327 (2008) 442-452
49. Fishel M.L., Delaney S.M., Friesen L.D., Hansen R.J., Zuhowski E.G.M., Moschel R.C., Egorin M.J., and Dolan M.E. Enhancement of platinum-induced cytotoxicity of O6-benzylguanine. Mol. Cancer Ther. 2 (2003) 633-640
50. Erkmen K., Egorin M.J., Reyno L.M., Morgan R., and Doroshow J.H. Effects of storage on the binding of carboplatin to plasma proteins. Cancer Chemother. Pharmacol. 35 (1995) 254-256
51. Tell G., Damante G., Caldwell D., and Kelley M.R. The intracellular localization of APE1/Ref-1: more than a passive phenomenon?. Antioxid. Redox Signal. 7 (2005) 367-384
52. Tichy E.D., and Stambrook P.J. DNA repair in murine embryonic stem cells and differentiated cells. Exp. Cell. Res. 314 (2008) 1929-1936
53. Karagiannis T.C., Harikrishnan K.N., and El-Osta A. Disparity of histone deacetylase inhibition on repair of radiation-induced DNA damage on euchromatin and constitutive heterochromatin compartments. Oncogene 26 (2007) 3963-3971
54. Wunderlich V., Schutt M., Bottger M., and Graffi A. Preferential alkylation of mitochondrial deoxyribonucleic acid by N-methyl-N-nitrosourea. Biochem. J. 118 (1970) 99-109
55. Yakes F.M., and Van Houten B. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 514-519
56. Zastawny T.H., Dabrowska M., Jaskolski T., Klimarczyk M., Kulinski L., Koszela A., Szczesniewicz M., Sliwinska M., Witkowski P., and Olinski R. Comparison of oxidative base damage in mitochondrial and nuclear DNA. Free Radic. Biol. Med. 24 (1998) 722-725
57. Ozaki K., Kishikawa F., Tanaka M., Sakamoto T., Tanimura S., and Kohno M. Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs. Cancer Sci. 99 (2007) 376-384
58. Gorisch S.M., Wachsmuth M., Toth K.F., Lichter P., and Rippe K. Histone acetylation increases chromatin accessibility. J. Cell Sci. 118 (2005) 5825-5834
59. Minucci S., and Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6 (2006) 38-51
60. Kim M., Trinh B.N., Long T.I., Oghamian S., and Laird P.W. Dnmt1 deficiency leads to enhanced microsatellite instability in mouse embryonic stem cells. Nucleic Acids Res. 32 (2004) 5742-5749
61. Kim M.S., Baek J.H., Chakravarty D., Sidransky D., and Carrier F. Sensitization to UV-induced apoptosis by the histone deacetylase inhibitor trichostatin A (TSA). Exp. Cell Res. 306 (2003) 94-102
62. Piacentini P., Donadelli M., Costanzo C., Moore P.S., Palmieri M., and Scarpa A. Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Arch. 448 (2006) 797-804
63. Kurz E.U., Wilson S.E., Leader K.B., Sampey B.P., Allan W.P., Yalowich J.C., and Kroll D.J. The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines. Mol. Cancer Ther. 1 (2001) 121-131
64. Murr R., Loizou J.I., Yang Y.G., Cuenin C., Li H., Wang Z.Q., and Herceg Z. Hisotne acetylation by trrap-Tip60 modulates loading of repair proteins and repair of DNA double-strand breaks. Nat. Cell Biol. 8 (2006) 91-99
65. Bakkenist C.J., and Kastan M.B. DNA damage activates ATM through intermoleclar autophosphorylation and dimer dissociation. Nature 421 (2003) 499-506
66. Tate C.M., Lee J.-H., and Skalnik D.G. CXXC finger protein 1 contains redundant functional domains that support embryonic stem cell cytosine methylation, histone methylation, and differentiation. Mol. Cell. Biol. 29 (2009) 3817-3831
67. Fuks F., Burgers W.A., Brehm A., Hughes-Davies L., and Kouzarides T. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat. Genet. 24 (2000) 88-91
68. Gopalakrishnan S., Van Emburgh B.O., and Robertson K.D. DNA methylation in development and human disease. Mutat. Res. 1 (2008) 30-38
69. Lehnertz B., Ueda Y., Derijck A.H., Braunschweig U., Perez-Burgos L., Kubicek S., Chen T., Li E., Jenuwein T., and Peters A. Suv39h-mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin. Curr. Biol. 13 (2003) 1192-1200
70. Paulsen M., and Ferguson-Smith A.C. DNA methylation in genomic imprinting, development, and disease. J. Pathol. 195 (2001) 97-110
71. Szyf M. DNA methylation and demethylation as targets for anticancer therapy. Biochemistry 70 (2005) 651-669
72. Tamaru H., and Selker E.U. A histone H3 methyltransferase controls DNA methylation in Neurospora crassa. Nature 414 (2001) 277-283
73. Weissmann F., Muyrers-Chen I., Musch T., Stach D., Wiessler M., Paro R., and Lyko F. DNA hypermethylation in Drosophila melanogaster causes irregular chromosome condensation and dysregulation of epigenetic hisone modifications. Mol. Cell. Biol. 23 (2003) 2577-2586
74. Doetsch P.W., and Cunningham R.P. The enzymology of apurinic/apyrimidinic endonucleases. Mutat. Res. 236 (1990) 173-201
75. Bobola M.S., Finn L.S., Ellenbogen R.G., Geyer J.R., Berger M.S., Braga J.M., Meade E.H., Gross M.E., and Silber J.R. Apurinic/apyrimidinic endonuclease activity is associated with response to radiation and chemotherapy in medulloblastoma and primitive neuroectodermal tumors. Clin. Cancer Res. 11 (2005) 7405-7414
76. Lau J.P., Weatherdon K.L., Skalski V., and Hedley D.W. Effects of gemcitabine on APE/ref-1 endonuclease activity in pancreatic cancer cells, and the therapeutic potential of antisense oligonucleotides. Br. J. Cancer 91 (2004) 1166-1173
77. Evans A.R., Limp-Foster M., and Kelley M.R. Going APE over ref-1. Mutat. Res. 461 (2000)
78. Silber J.R., Bobola M.S., Blank A., Schoeler K.D., Haroldson P.D., Huynh M.B., and Kolstoe D.D. The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress. Clin. Cancer Res. 8 (2002) 3008-3038
79. Meira L.B., Devaraj S., Kisby G.E., Burns D.K., Daniel R.L., Hammer R.E., Grundy S., Jialal I., and Friedberg E.C. Heterozygosity for the mouse Apex gene results in phenotypes associated with oxidative stress. Cancer Res. 61 (2001) 5552-5557
80. Raffoul J.J., Cabelof D.C., Nakamura J., Meira L.B., Friedberg E.C., and Heydari A.R. Apurinic/Apyrimidinic endonuclease (APE/REF-1) haploinsufficient mice display tissue-specific differences in DNA polymerase beta-dependent base excision repair. J. Biol. Chem. 279 (2004) 18425-18433
81. Huamani J., McMahan C.A., Herbert D.C., Reddick R., McCarrey J.R., MacInnes M.I., Chen D.J., and Walter C.A. Spontaneous mutagenesis is enhanced in Apex heterozygous mice. Mol. Cell. Biol. 24 (2004) 8145-8153
82. Lee J.-H., and Skalnik D.G. CpG binding protein is a nuclear matrix- and euchromatin-associated protein localized to nuclear speckles containing human trithorax: identification of nuclear matrix targeting signals. J. Biol. Chem. 277 (2002) 42259-42267
83. Harrison L., Ascione A.G., Wilson D.M., and Demple B. Characterization of the promoter region of the human apurinic endonuclease gene (APE). J. Biol. Chem. 270 (1995) 5556-5564
84. Bapat A., Fishel M., and Kelley M.R. Going Ape as an approach to cancer therapeutics. Antioxid. Redox Signal 11 (2009) 651-668
85. Donawho C.K., Luo Y., Luo Y., Penning T.D., Bauch J.L., Bouska J.J., Bontcheva-Diaz V.D., Cox B.F., DeWeese T.L., Dillehay L.E., Ferguson D.C., Ghoreishi-Haack N.S., Grimm D.R., Guan R., Han E.K., Holley-Shanks R.R., Hristov B., Idler K.B., Jarvis K., Johnson E.F., Kleinberg L.R., Klinghofer V., Lasko L.M., Liu X., March K.C., McGonigal T.P., Meulbroek J.A., Olson A.M., Palma J.P., Rodriguez L.E., Shi Y., Stavropoulos J.A., Tsurutani A.C., Zhu G.D., Rosenberg S.H., Giranda V.L., and Frost D.J. ABT-888, an orally active poly (ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclincal tumor models. Clin. Cancer Res. 13 (2007) 2728-2737
86. Mason K.A., Valdecanas D., Hunter N.R., and Milas L. INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin. Invest. New Drugs 26 (2008) 1-5
87. Menoni H., Gasparutto D., Hamiche A., Cadet J., Dimitrov S., Bouvet P., and Angelov D. ATP-dependent chromatin remodeling is required for base excision repair in conventional but not in variant H2A.Bbd nucleosomes. Mol. Cell. Biol. 7 (2007) 437-447
88. Green C.M., and Almouzni G. Local action of the chromatin assembly factor CAF1 at sites of nucleotide excision repair in vivo. EMBO J. 22 (2003) 5163-5174
89. Smerdon M.J., and Lieberman M.W. Nucleosome rearrangement in human chromatin during UV-induced DNA-repair synthesis. Proc. Natl. Acad. Sci. U.S.A. 75 (1978) 422-428
90. Harrison L., Hatahet Z., and Wallace S.S. In vitro repair of synthetic ionizing radiation-induced multiply damaged DNA sites. J. Mol. Biol. 290 (1999) 667-684
91. Op het Veld C.W., Jansen J., Zdzienicka M.Z., Vrieling H., and van Zeeland A.A. Methyl methanesulfonate-induced hprt mutation spectra in the Chinese hamster cell line CHO9 and its xrcc1-deficient derivative EM-C11. Mutat. Res. 398 (1998) 83-92
92. David S.S., O'Shea V.L., and Kundu S. Base-excision repair of oxidative DNA damage. Nature 447 (2007) 941-950
93. Denny B.J., Wheelhouse R.T., Stevens M.F., Tsang L.L., and Slack J.A. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 33 (1994) 9045-9051
94. Meresse P., Dechaux E., Monneret C., and Bertounesque E. Etoposide: discovery and medicinal chemistry. Curr. Med. Chem. 11 (2004) 2443-2466
95. Rabik C.A., and Dolan M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev. 33 (2007) 9-23
96. Longo-Sorbello G.S., and Bertino J.R. Current understanding of methotrexate pharmacology and efficacy in acute leukemias. Use of newer antifolates in clinical trials. Haematologica 86 (2001) 121-127
97. McGuire J.J. Anticancer antifolates: current status and future directions. Curr. Pharm. Des. 9 (2003) 2593-2613
98. Abal M., Andreu J.M., and Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr. Cancer Drug Targets 3 (2003) 193-203